

DAFTAR PUSTAKA

- Abbafati, C., Abbas, K.M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., dkk., 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, **396**: 1204–1222.
- Ali, T., Sisay, M., Tariku, M., Mekuria, A.N., dan Desalew, A., 2021. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. *PLoS ONE*, **16**: 6–17.
- Alia, S., Hidayati, H.B., Hamdan, M., Nugraha, P., Fahmi, A., Turchan, A., dkk., 2022. Penyakit Parkinson: Tinjauan Tentang Salah Satu Penyakit Neurodegeneratif yang Paling Umum. *Aksona*, **1**: 95–99.
- Angelica, M.D. dan Fong, Y., 2015. Diagnostic and treatment of dystonias. *Neurol Clin. Elsevier Inc*, **141**: 520–529.
- Azmi, A.N. dan Desrini, S., 2016. A cross sectional study of trihexyphenidyl utilization on patient receiving antipsychotic therapy. *Jurnal Kedokteran dan Kesehatan Indonesia*, **7**: 102–108.
- Bangwal, R., Bisht, S., Saklani, S., Garg, S., dan Dhayani, M., 2020. Psychotic Disorders, Definition, Sign and Symptoms, Antipsychotic Drugs, Mechanism of Action, Pharmacokinetics & Pharmacodynamics with Side Effects & Adverse Drug Reactions: Updated Systematic Review Article. *Journal of Drug Delivery and Therapeutics*, **10**: 163–172.
- Berna, F., Misdrahi, D., Boyer, L., Aouizerate, B., Brunel, L., Capdevielle, D., dkk., 2015. Akathisia: Prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. *Schizophrenia Research*, **169**: 255–261.
- Boer, G. de, Alfonsius de Bie, R.M., dan Sylvain Swinnen, B.E.K., 2024. Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders. *Current Neuropharmacology*, **22**: 2284–2297.
- Budiarti, R., 2021. Oropharyngeal dysphagia in extrapyramidal syndrome. *Oto Rhino Laryngologica Indonesiana*, **51**: 80–87.
- Bymaster, F.P., Felder, C.C., Tzavara, E., Nomikos, G.G., Calligaro, D.O., dan

- Mckinzie, D.L., 2003. Muscarinic mechanisms of antipsychotic atypicality. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **27**: 1125–1143.
- Chokhawala, 2023. 'Antipsikotik Medications', *National Library of Medicine*. URL: <https://www.ncbi.nlm.nih.gov/books/NBK519503/>.
- Chouinard, G., Cosci, F., Chouinard, V.A., dan Alphs, L., 2024. The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties. *Psychotherapy and Psychosomatics*, **92**: 359–366.
- Chouinard, G. dan Margolese, H.C., 2005. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). *Schizophrenia Research*, **76**: 247–265.
- Courey, T.J., 2007. Detection, Prevention and Management of Extrapyramidal Symptoms. *The Journal for Nurse Practitioners-JNP*, 5–10.
- Dahlan, M.S., 2010. *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran Dan Kesehatan*, Journal GEEJ.
- Desai, N., Patel, P.B., Shah, S., Patel, T.K., Shah, S.N., dan Vatsala, E., 2018. Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India—a cross-sectional study. *International Journal of Psychiatry in Clinical Practice*, **22**: 101–108.
- Desmarais, J.E., Beauclair, L., Annable, L., Bélanger, M.C., Kolivakis, T.T., dan Margolese, H.C., 2014. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. *Therapeutic Advances in Psychopharmacology*, **4**: 257–267.
- Dipiro, J, T., Yee., dan Posey, L., 2022. PHARMACOTHERAPY A Pathophysiologic : Approach Eleventh Edition, dalam: *Medicine (United Kingdom)*. hal. 1–7727.
- Divac, N., Prostran, M., Jakovcevski, I., dan Cerovac, N., 2014. Second-generation antipsychotics and extrapyramidal adverse effects. *BioMed Research International*, **2014**: .
- Farah, F.H., 2018. Schizophrenia: An overview. *Asian Journal of Pharmaceutics*, **12**: 77–87.

- Gogos, A., Sbisà, A.M., Sun, J., Gibbons, A., Udawela, M., dan Dean, B., 2015. A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, **2015**: .
- Harvey, A.R., Baker, L.B., Reddihough, D.S., Scheinberg, A., dan Williams, K., 2018. Trihexyphenidyl for dystonia in cerebral palsy. *Cochrane Database of Systematic Reviews*, **2018**: .
- Hooten, R.S.D.W.M., 2023. 'Extrapyramidal Symptoms', *National Library of Medicine*. URL: <https://www.ncbi.nlm.nih.gov/books/NBK534115/>.
- Ikawati, Z., 2014. *Farmakoterapi Penyakit Sistem Syaraf Pusat*. Bursa Ilmu, Yogyakarta.
- Indriani, A., Ardiningrum, W., dan Febrianti, Y., 2020. Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta. *Majalah Farmasetika.*, **4**: 201–211.
- Jankovic, J., 2008. Parkinson's disease: Clinical features and diagnosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **79**: 368–376.
- Jankovic, J., 2013. Medical treatment of dystonia. *Baylor College of Medicine, Houston*, **28**: 1001–1012.
- Jellinger, K.A., 2019. *Neuropathology and Pathogenesis of Extrapyramidal Movement Disorders: A Critical Update—I. Hypokinetic-Rigid Movement Disorders*, *Journal of Neural Transmission*. Springer Vienna.
- Juncal-Ruiz, M., Ramirez-Bonilla, M., Gomez-Arnau, J., Ortiz-Garcia de la Foz, V., Suarez-Pinilla, P., Martinez-Garcia, O., dkk., 2017. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. *Psychopharmacology*, **234**: 2563–2570.
- Kemenkes, 2023. Survei Kesehatan Indonesia 2023 (SKI). *Kemenkes*, 235.
- Kemenkes RI, 2014. Undang-Undang Republik Indonesia Nomor 18 Tahun 2014 Tentang Kesehatan Jiwa. *Undang-Undang*, **85**: 2071–2079.
- Kemenkes RI, 2015. Keputusan Menteri Kesehatan RI Nomor HK.02.02/MENKES/73/2015 Tentang Pedoman Nasional Pelayanan Kedokteran Jiwa. *Pedoman*, **151**: 10–17.

- Kemenkes RI, 2023. Undang-Undang Republik Indonesia Nomor 17 Tahun 2023 Tentang Kesehatan. *Undang-Undang*, 1–300.
- Kementrian Kesehatan RI, 2023. Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/2197/2023 Tentang Formularium Nasional 1–219.
- Lexidrug, 2024. 'Lexidrug', *Wolters Kluwer*. URL: <https://www.wolterskluwer.com/en/solutions/uptodate/pro/lexidrug>.
- Lindgren, M., Therman, S., Avellan, A., From, T., Hietala, J., Holm, M., dkk., 2022. Extrapyramidal symptoms predict cognitive performance after first-episode psychosis. *Schizophrenia*, **8**: 1–7.
- López-Álvarez, J., Sevilla-Llewellyn-Jones, J., dan Agüera-Ortiz, L., 2019. Anticholinergic Drugs in Geriatric Psychopharmacology. *Frontiers in Neuroscience*, **13**: 1–15.
- Maher, S., Cunningham, A., O’Callaghan, N., Byrne, F., Mc Donald, C., McInerney, S., dkk., 2016. Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. *Therapeutic Advances in Psychopharmacology*, **6**: 178–184.
- Mas, S., Gassó, P., Lafuente, A., Bioque, M., Lobo, A., González-Pinto, A., dkk., 2016. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes. *Pharmacogenomics Journal*, **16**: 439–445.
- McDonagh, M.S., Dana, T., Selph, S., Devine, E.B., Cantor, A., Bougatsos, C., dkk., 2020. Updating the comparative evidence on second- generation antipsychotic use with schizophrenia. *Psychiatric Research and Clinical Practice*, **2**: 76–87.
- Mehta, S.H., Morgan, J.C., dan Sethi, K.D., 2015. Drug-induced movement disorders. *Neurologic Clinics*, **33**: 153–174.
- Miyamoto, S., Duncan, G.E., Marx, C.E., dan Lieberman, J.A., 2005. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Molecular Psychiatry*, **10**: 79–104.
- Monteleone, P., Cascino, G., Monteleone, A.M., Rocca, P., Rossi, A., Bertolino, A., dkk., 2021. Prevalence of antipsychotic-induced extrapyramidal symptoms

and their association with neurocognition and social cognition in outpatients with schizophrenia in the “real-life.” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **109**: .

Mu, E., Gurvich, C., dan Kulkarni, J., 2024. Estrogen and psychosis — a review and future directions. *Archives of Women’s Mental Health*, **27**: 877–885.

Musdalifah, W., Susanti, R., dan Robiyanto, 2019. Evaluasi Penggunaan Obat Triheksifenidil Sebagai Terapi Adjuvan Pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Daerah Sungai Bangkong Pontianak. *Jurnal Mahasiswa Farmasi Fakultas ...*, **4**: 1–12.

Nurnberger, J.I., Austin, J., Berrettini, W.H., Besterman, A.D., DeLisi, L.E., Grice, D.E., dkk., 2019. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort. *Journal of Clinical Psychiatry*, **80**: .

Ogino, S., Miyamoto, S., Miyake, N., dan Yamaguchi, N., 2014. Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. *Psychiatry and Clinical Neurosciences*, **68**: 37–49.

Ortiz-Orendain, J., Castiello-De Obeso, S., Colunga-Lozano, L., Hu, Y., Maayan, N., dan Adams, C., 2018. Antipsychotic Combinations for Schizophrenia. *Schizophrenia Bulletin*, **44**: 15–17.

Owen, M.J., Sawa, A., dan Mortensen, P.B., 2016. Schizophrenia. *The Lancet*, **388**: 86–97.

Panel, U.E., 2023. American Geriatrics Society 2023 updated AGS Beers Criteria[®] for potentially inappropriate medication use in older adults.

Peluso, M.J., Lewis, S.W., Barnes, T.R.E., dan Jones, P.B., 2012. Extrapyramidal motor side-effects of first and second-generation antipsychotic drugs. *British Journal of Psychiatry*, **200**: 387–392.

Pereira, S.R. dan Albert, M., 2017. Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms. *Cochrane Database of Systematic Reviews*, **2017**: .

Rahaya, A. dan Cahaya, N., 2016. Studi Retrospektif Penggunaan Trihexyfenidil Pada Pasien Skizofrenia Rawat Inap Yang Mendapat Terapi Antipsikotik Di

- Rumah Sakit Jiwa Sambang Lihum. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, **2**: 124–131.
- Rusdi, M., 2013. *Diagnosis Gangguan Jiwa, Rujukan Ringkasan PPDGJ-III Dan DSM-5*. Bagian Ilmu Kedokteran Jiwa FK Unika Atma Jaya, Jakarta.
- Shankar, P.R. dan Alshakka, M.A., 2019. *Clinical Pharmacy and Therapeutics Sixth Edition*, Journal of Chitwan Medical College.
- Sheikh, W., 2019. Prophylactic Use of Trihexyphenidyl (Artane) in Schizophrenia and Psychosis: A Critical Review of Literature to Guide for Evidence Based Practice in Zambia. *Medical Journal of Zambia*, **46**: 133–139.
- Shettima, F.B., Sheikh, T.L., Wakil, M.A., Abdulaziz, M., Rabebbe, I.B., dan Abdulmalik, J.O., 2023. Prevalence and Correlates of Extrapyramidal Side Effects Among Patients with Schizophrenia Spectrum Disorders on Typical and Atypical Antipsychotics. *Archives of psychiatry research*, **59**: 225–240.
- Sockalingam, S., Shammi, C., dan Remington, G., 2007. Clozapine-induced hypersalivation: A review of treatment strategies. *Canadian Journal of Psychiatry*, **52**: 377–384.
- Solmi, M., Seitidis, G., Mavridis, D., Correll, C.U., Dragioti, E., Guimond, S., dkk., 2023. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. *Molecular Psychiatry*, **28**: 5319–5327.
- Stroup, T.S. dan Gray, N., 2018. Management of common adverse effects of antipsychotic medications. *World Psychiatry*, **17**: 341–356.
- Temtem, G., Woldu, M., Berha, A., Shibeshi, W., Teferra, S., dan Engidawork, E., 2023. Drug therapy problems in patients with schizophrenia: A cross-sectional study. *Clinical Medicine Insights: Psychiatry*, **14**: 1–10.
- WHO, 2022. 'World Health Organization', *World Health Organization*. URL: <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>.
- Zhang, K., Miao, S., Yao, Y., Yang, Y., Shi, S., Luo, B., dkk., 2023. Efficacy and safety of prophylactic use of benzhexol after risperidone treatment. *Heliyon*, **9**: .